Acurx Pharmaceuticals, Inc.

  • Home
  • About
    • Management / Consultants
    • Scientific / Corporate Advisors
    • Board of Directors
  • Pipeline
    • Overview
    • Ibezapolstat
    • ACX-375C
    • Publications
  • News & Media
    • Press Releases
    • Presentations
    • Videos
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Ph2 Clinical Trial
  • Contact

Presentations

News & Media

News & Media

  • Press Releases
  • Presentations
  • Videos
ID Week Presentation (October 2022) Development Update on Ibezapolstat for the Treatment of Clostridioides difficile infection: Focus on the Microbiome

ID Week Presentation (October 2022) Development Update on Ibezapolstat for the Treatment of Clostridioides difficile infection: Focus on the Microbiome

Poster Presentation ID Week (October 2022) Investigating the Gram Positive Selective Spectrum of Ibezapolstat, a First in Class DNA Polymerase IIIC (Pol IIIC) Inhibitor

Poster Presentation ID Week (October 2022) Investigating the Gram Positive Selective Spectrum of Ibezapolstat, a First in Class DNA Polymerase IIIC (Pol IIIC) Inhibitor

Poster Presentation and Abstract from ID Week (October 2021) titled “An Open-label Phase 2a study of Ibezapolstat, a Unique Gram-positive Selective Spectrum (GPSS™) Antibiotic, for Patients with Clostridioides difficile Infection.” presented by Dr. Kevin Garey, Professor and Chair, University of Houston College of Pharmacy”

Poster Presentation and Abstract from ID Week (October 2021) titled “An Open-label Phase 2a study of Ibezapolstat, a Unique Gram-positive Selective Spectrum (GPSS™) Antibiotic, for Patients with Clostridioides difficile Infection.” presented by Dr. Kevin Garey, Professor and Chair, University of Houston College of Pharmacy”

DNA polymerase IIIC Inhibitor ibezapolstat, first of a new class of antibiotics with a novel mechanism of action: Clinical Trial Update

DNA polymerase IIIC Inhibitor ibezapolstat, first of a new class of antibiotics with a novel mechanism of action: Clinical Trial Update

ID Week Oral Presentation of Phase 1 Data, presented by Dr. Kevin Garey, Professor & Chair, Department of Pharmacy Practice and Translational Research, University of Houston

ID Week Oral Presentation of Phase 1 Data, presented by Dr. Kevin Garey, Professor & Chair, Department of Pharmacy Practice and Translational Research, University of Houston

Time-kill Kinetics of the Novel Antibacterial Agent ACX-362E against Clostridioides difficile

Time-kill Kinetics of the Novel Antibacterial Agent ACX-362E against Clostridioides difficile

Scientific Presentation

In Vitro Activity of the Novel Antibacterial ACX-362E against Clostridioides difficile

In Vitro Activity of the Novel Antibacterial ACX-362E against Clostridioides difficile

Scientific Presentation

RSS
© 2023 Acurx Pharmaceuticals, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap